RESULTS
1. Improvement of symptoms and signs: Symptoms and signs were compared before and after therapy in the same individual. After therapy, symptoms and signs were controlled or improved as shown in Tables I and II. 2. Improvement of cardiac function: Before treatment, cardiac function was evaluated to be Grade III in 8 and Grade IV in 7 patients. After treatment in 14 of the 15 patients, there was improvement in cardiac function; only 5 patients were estimated to be in Grade III and 1 in Grade IV.
3. Effects on ECG and hemodynamics: After diltiazem therapy, follow-up ECG showed 64% of cases of multiple, multifocal and parasystolic premature arrhythmias were controlled, but without any significant changes in cardiac block or QRS patterns. 66.7% of the cases showed less deviation of ST segment and lowering or inversion of T wave.
The results of Swan-Ganz floating catheterization carried out in 3 patients are shown in Table IV. 4. Effects on the size of cardiac silhouette: There were marked decreases in the area of the cardiac silhouette on X-ray after therapy in both absolute Table III . Improvement in Cardiac Function and relative terms, the changes in Group I were more obvious (p<0.01).
The results are shown in Table V. 5. Changes in indexes derived from echocardiograms (Table VI) : After diltiazem therapy, the left atrial dimension (LAD), SV, CO and CI increased significantly (p<0.05 or <0.01).
The elevation of EF and lowering of TPR were also significant (p<0.01).
In Group I the decreases in LVEDD and LVEDV were significant (p<0.05), while the changes in Group II were not.
6. Changes in heart rate and blood pressure after therapy: After therapy the heart rates increased slightly, and the blood pressure decreased slightly but within normal ranges (p>0.05). Right: Cardiac silhouette returning to normal size and no pleural effusion after 6 months of diltiazem therapy.
7. Case reports: Patient 1, a 16 year old female, suffered from palpitations, dyspnea, suffocation, frothy bloody sputum and pitting edema intermittently for 20 months, and was diagnosed as having primary congestive cardiomyopathy.
She was unresponsive to conventional treatment, and was then treated with diltiazem. The X-ray (Fig.1) enlargement and increased lung markings on P-A view before treatment. Her symptoms and signs were greatly improved on diltiazem therapy. After 6 months of therapy, the cardiac silhouette decreased by 24.6% and lung markings decreased as shown on the right side.
Patient 2, a 30 year old female, developed palpitations, dyspnea, orthopnea and edema of the lower extremities 6 months prior to admission and was diagnosed as having primary congestive cardiomyopathy.
The X-ray (Fig.2) showed marked generalized cardiac enlargement with pleural effusion on the left side, not responding to conventional therapy. After 6 months of therapy, the cardiac silhouette was returning to normal size. 
